A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation

The goal of this clinical research study is to find the highest tolerable dose of AG-120 (also known as ivosidenib) that can be given to patients with acute myelogenous leukemia (AML) or another type of blood disease (a disease affecting the blood or bone marrow), such as myelodysplastic syndrome (MDS). The safety of this drug will also be studied. This is the first study using AG-120 in humans.

Treatment Location: N/A

Sponsor: N/A

IRB Review and Approval Date: 12/15/2014

Recruitment Status: Closed

Projected Accrual: N/A

Phone Number: 1-877-MDA-6789

clinicaltrials.gov NCT No: NCT02074839